| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Hamid Reza Fard Masoumi, Mahiran Basri, Wan Sarah Samiun, Zahra Izadiyan, Chaw Jiang Li. Enhancement of encapsulation efficiency of nanoemulsion-containing aripiprazole for the treatment of schizophrenia using mixture experimental design. International journal of nanomedicine. vol 10. 2016-08-18. PMID:26508853. |
aripiprazole is considered as a third-generation antipsychotic drug with excellent therapeutic efficacy in controlling schizophrenia symptoms and was the first atypical anti-psychotic agent to be approved by the us food and drug administration. |
2016-08-18 |
2023-08-13 |
Not clear |
| Delbert G Robinson, Juan A Gallego, Majnu John, Georgios Petrides, Youssef Hassoun, Jian-Ping Zhang, Leonardo Lopez, Raphael J Braga, Serge M Sevy, Jean Addington, Charles H Kellner, Mauricio Tohen, Melissa Naraine, Natasha Bennett, Jessica Greenberg, Todd Lencz, Christoph U Correll, John M Kane, Anil K Malhotr. A Randomized Comparison of Aripiprazole and Risperidone for the Acute Treatment of First-Episode Schizophrenia and Related Disorders: 3-Month Outcomes. Schizophrenia bulletin. vol 41. issue 6. 2016-07-20. PMID:26338693. |
a randomized comparison of aripiprazole and risperidone for the acute treatment of first-episode schizophrenia and related disorders: 3-month outcomes. |
2016-07-20 |
2023-08-13 |
human |
| Andrea de Bartolomeis, Carmine Tomasetti, Felice Iasevol. Update on the Mechanism of Action of Aripiprazole: Translational Insights into Antipsychotic Strategies Beyond Dopamine Receptor Antagonism. CNS drugs. vol 29. issue 9. 2016-07-15. PMID:26346901. |
this review aims to recapitulate the main neurobiological effects of aripiprazole and discuss the potential implications for upcoming improvements in schizophrenia therapy based on dopamine modulation beyond d2r antagonism. |
2016-07-15 |
2023-08-13 |
Not clear |
| Jennifer E Thomas, Joshua Caballero, Catherine A Harringto. The Incidence of Akathisia in the Treatment of Schizophrenia with Aripiprazole, Asenapine and Lurasidone: A Meta-Analysis. Current neuropharmacology. vol 13. issue 5. 2016-07-15. PMID:26467415. |
the incidence of akathisia in the treatment of schizophrenia with aripiprazole, asenapine and lurasidone: a meta-analysis. |
2016-07-15 |
2023-08-13 |
Not clear |
| Steven G Potkin, Adrian Pred. Aripiprazole once-monthly long-acting injectable for the treatment of schizophrenia. Expert opinion on pharmacotherapy. vol 17. issue 3. 2016-07-14. PMID:26864352. |
aripiprazole once-monthly long-acting injectable for the treatment of schizophrenia. |
2016-07-14 |
2023-08-13 |
Not clear |
| Steven G Potkin, Adrian Pred. Aripiprazole once-monthly long-acting injectable for the treatment of schizophrenia. Expert opinion on pharmacotherapy. vol 17. issue 3. 2016-07-14. PMID:26864352. |
an extended formulation, aripiprazole 400 mg once-monthly (aom 400) lai (aom lai), received regulatory approval in the year 2013 for the treatment of schizophrenia. |
2016-07-14 |
2023-08-13 |
Not clear |
| Dieter Naber, Karina Hansen, Carlos Forray, Ross A Baker, Christophe Sapin, Maud Beillat, Timothy Peters-Strickland, Anna-Greta Nylander, Peter Hertel, Henrik Steen Andersen, Anna Eramo, Jean-Yves Loze, Steven G Potki. Qualify: a randomized head-to-head study of aripiprazole once-monthly and paliperidone palmitate in the treatment of schizophrenia. Schizophrenia research. vol 168. issue 1-2. 2016-07-06. PMID:26232241. |
qualify: a randomized head-to-head study of aripiprazole once-monthly and paliperidone palmitate in the treatment of schizophrenia. |
2016-07-06 |
2023-08-13 |
Not clear |
| Dieter Naber, Karina Hansen, Carlos Forray, Ross A Baker, Christophe Sapin, Maud Beillat, Timothy Peters-Strickland, Anna-Greta Nylander, Peter Hertel, Henrik Steen Andersen, Anna Eramo, Jean-Yves Loze, Steven G Potki. Qualify: a randomized head-to-head study of aripiprazole once-monthly and paliperidone palmitate in the treatment of schizophrenia. Schizophrenia research. vol 168. issue 1-2. 2016-07-06. PMID:26232241. |
to directly compare aripiprazole once-monthly 400mg (aom 400) and paliperidone palmitate once-monthly (pp) on the heinrichs-carpenter quality-of-life scale (qls), a validated health-related quality of life and functioning measure in schizophrenia. |
2016-07-06 |
2023-08-13 |
Not clear |
| Timothy Peters-Strickland, Ross A Baker, Robert D McQuade, Na Jin, Anna Eramo, Pamela Perry, Brian R Johnson, Anna Duca, Raymond Sanche. Aripiprazole once-monthly 400 mg for long-term maintenance treatment of schizophrenia: a 52-week open-label study. NPJ schizophrenia. vol 1. 2016-06-23. PMID:27336044. |
aripiprazole once-monthly 400 mg for long-term maintenance treatment of schizophrenia: a 52-week open-label study. |
2016-06-23 |
2023-08-13 |
Not clear |
| Yoshiteru Takekita, Chiara Fabbri, Masaki Kato, Shinpei Nonen, Shiho Sakai, Naotaka Sunada, Yosuke Koshikawa, Masataka Wakeno, Gaku Okugawa, Toshihiko Kinoshita, Alessandro Serrett. Antagonist and partial agonist at the dopamine D2 receptors in drug-naïve and non-drug-naïve schizophrenia: a randomized, controlled trial. European archives of psychiatry and clinical neuroscience. vol 265. issue 7. 2016-06-16. PMID:26016467. |
patients with schizophrenia were recruited and given perospirone or aripiprazole in a 12-week, flexible-dose, open-label, randomized controlled study. |
2016-06-16 |
2023-08-13 |
Not clear |
| Jingyuan Zhao, Xueqin Song, Xiaoqing Ai, Xiaojing Gu, Guangbiao Huang, Xue Li, Lijuan Pang, Minli Ding, Shuang Ding, Luxian L. Adjunctive Aripiprazole Treatment for Risperidone-Induced Hyperprolactinemia: An 8-Week Randomized, Open-Label, Comparative Clinical Trial. PloS one. vol 10. issue 10. 2016-06-10. PMID:26448615. |
the present study aimed to evaluate the efficacy and safety of adjunctive aripiprazole treatment in schizophrenia patients with risperidone-induced hyperprolactinemia. |
2016-06-10 |
2023-08-13 |
Not clear |
| C Sapin, M J Tempest, F Gaughran, M Beillat, P Robinson, M Treu. Aripiprazole Once-Monthly is a Cost-Effective Therapeutic Option in the Maintenance Treatment of Schizophrenia: Results from a Markov Model. Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research. vol 17. issue 7. 2016-06-10. PMID:27201270. |
aripiprazole once-monthly is a cost-effective therapeutic option in the maintenance treatment of schizophrenia: results from a markov model. |
2016-06-10 |
2023-08-13 |
Not clear |
| Ji-Young Jeon, Soo-Wan Chae, Min-Gul Ki. Population pharmacokinetics of aripiprazole in healthy Korean subjects. International journal of clinical pharmacology and therapeutics. vol 54. issue 4. 2016-06-02. PMID:26902506. |
aripiprazole is widely used to treat schizophrenia and bipolar disorder. |
2016-06-02 |
2023-08-13 |
human |
| Ather Munee. The Treatment of Adult Bipolar Disorder with Aripiprazole: A Systematic Review. Cureus. vol 8. issue 4. 2016-05-18. PMID:27190727. |
aripiprazole is a novel antipsychotic initially approved for the treatment of schizophrenia but soon found to be effective in bipolar disorder. |
2016-05-18 |
2023-08-13 |
human |
| Arija Maat, Wiepke Cahn, Harm J Gijsman, Johannes E Hovens, René S Kahn, André Alema. Open, randomized trial of the effects of aripiprazole versus risperidone on social cognition in schizophrenia. European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology. vol 24. issue 4. 2016-05-06. PMID:24418213. |
open, randomized trial of the effects of aripiprazole versus risperidone on social cognition in schizophrenia. |
2016-05-06 |
2023-08-12 |
Not clear |
| Arija Maat, Wiepke Cahn, Harm J Gijsman, Johannes E Hovens, René S Kahn, André Alema. Open, randomized trial of the effects of aripiprazole versus risperidone on social cognition in schizophrenia. European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology. vol 24. issue 4. 2016-05-06. PMID:24418213. |
the goal of this 8-week, randomized, multicenter, open-label study was to examine the effects of aripiprazole and risperidone on social cognition and neurocognition in individuals with schizophrenia. |
2016-05-06 |
2023-08-12 |
Not clear |
| John M Kane, Raymond Sanchez, Ross A Baker, Anna Eramo, Timothy Peters-Strickland, Pamela P Perry, Brian R Johnson, Lan-Feng Tsai, William H Carson, Robert D McQuade, W Wolfgang Fleischhacke. Patient-Centered Outcomes with Aripiprazole Once-Monthly for Maintenance Treatment in Patients with Schizophrenia: Results From Two Multicenter, Randomized, Double-Blind Studies. Clinical schizophrenia & related psychoses. vol 9. issue 2. 2016-05-05. PMID:25711509. |
patient-centered outcomes with aripiprazole once-monthly for maintenance treatment in patients with schizophrenia: results from two multicenter, randomized, double-blind studies. |
2016-05-05 |
2023-08-13 |
Not clear |
| John M Kane, Raymond Sanchez, Ross A Baker, Anna Eramo, Timothy Peters-Strickland, Pamela P Perry, Brian R Johnson, Lan-Feng Tsai, William H Carson, Robert D McQuade, W Wolfgang Fleischhacke. Patient-Centered Outcomes with Aripiprazole Once-Monthly for Maintenance Treatment in Patients with Schizophrenia: Results From Two Multicenter, Randomized, Double-Blind Studies. Clinical schizophrenia & related psychoses. vol 9. issue 2. 2016-05-05. PMID:25711509. |
to further characterize the clinical profile of long-term treatment with aripiprazole once-monthly 400 mg (aom 400) by examining patient-centered outcomes in adults with schizophrenia. |
2016-05-05 |
2023-08-13 |
Not clear |
| Istvan M Majer, Fiona Gaughran, Christophe Sapin, Maud Beillat, Maarten Treu. Efficacy, tolerability, and safety of aripiprazole once-monthly versus other long-acting injectable antipsychotic therapies in the maintenance treatment of schizophrenia: a mixed treatment comparison of double-blind randomized clinical trials. Journal of market access & health policy. vol 3. 2016-04-28. PMID:27123183. |
efficacy, tolerability, and safety of aripiprazole once-monthly versus other long-acting injectable antipsychotic therapies in the maintenance treatment of schizophrenia: a mixed treatment comparison of double-blind randomized clinical trials. |
2016-04-28 |
2023-08-13 |
Not clear |
| Istvan M Majer, Fiona Gaughran, Christophe Sapin, Maud Beillat, Maarten Treu. Efficacy, tolerability, and safety of aripiprazole once-monthly versus other long-acting injectable antipsychotic therapies in the maintenance treatment of schizophrenia: a mixed treatment comparison of double-blind randomized clinical trials. Journal of market access & health policy. vol 3. 2016-04-28. PMID:27123183. |
recently, the intramuscular once-monthly formulation of aripiprazole received marketing approval in europe and the united states for schizophrenia. |
2016-04-28 |
2023-08-13 |
Not clear |